Hyperion Biosystems Analysis: $29M Raised
What is Hyperion Biosystems?
Hyperion Biosystems develops diagnostic devices that utilize computer vision and physics-based algorithms to enhance assay performance. The company focuses on improving sensitivity and specificity in point-of-care and at-home testing markets. Their proprietary technology aims to deliver high performance at competitive prices.
Location
500 Arsenal St, Watertown, Massachusetts 02472, United States
Employees
11-50
Founded
2013
Funding Status
Series B
Product Features & Capabilities
- HALO® for assay performance enhancement
- HELIOS™ for multiplex detection of circulating tumor and cell-free DNA
Use Cases
Identify false positives in diagnostic assays; Mitigate assay defects for improved performance; Enhance sensitivity in point-of-care testing; Support multiplex detection in oncology diagnostics; Deliver custom solutions rapidly for clients
Other Considerations
Formerly C2Sense, Inc.; 10x average sensitivity enhancement; 10,000 assays run with proprietary algorithms; Partnerships with industry leaders; Recent licensing agreement with Colorcon for anti-counterfeiting technology
See something that needs updating? Suggest edits to this profile.